Brokerages predict that Neuronetics Inc (NASDAQ:STIM) will report earnings per share (EPS) of ($0.45) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Neuronetics’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.42). Neuronetics posted earnings of ($0.35) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 28.6%. The company is expected to issue its next quarterly earnings results on Tuesday, March 3rd.
On average, analysts expect that Neuronetics will report full-year earnings of ($1.63) per share for the current year, with EPS estimates ranging from ($1.66) to ($1.59). For the next year, analysts anticipate that the business will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.75) to ($1.46). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Neuronetics.
Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.04. Neuronetics had a negative return on equity of 44.10% and a negative net margin of 45.35%. The company had revenue of $16.00 million during the quarter, compared to the consensus estimate of $16.13 million.
Several equities research analysts recently commented on STIM shares. BTIG Research reduced their price objective on Neuronetics to $11.00 and set an “average” rating for the company in a report on Wednesday, November 6th. ValuEngine upgraded Neuronetics from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research downgraded Neuronetics from a “buy” rating to a “hold” rating in a report on Saturday, November 9th.
NASDAQ STIM traded down $0.04 during trading hours on Wednesday, hitting $4.50. The company’s stock had a trading volume of 154,701 shares, compared to its average volume of 110,064. Neuronetics has a 12 month low of $3.96 and a 12 month high of $21.25. The company’s 50 day simple moving average is $6.46 and its two-hundred day simple moving average is $9.99. The company has a market cap of $80.49 million, a P/E ratio of -1.67 and a beta of 0.66. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.36 and a quick ratio of 4.23.
In other news, CFO Stephen Furlong purchased 22,959 shares of the business’s stock in a transaction on Friday, November 15th. The stock was acquired at an average cost of $4.40 per share, for a total transaction of $101,019.60. Also, Director Stephen M. Campe purchased 9,500 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were purchased at an average price of $4.26 per share, with a total value of $40,470.00. Following the completion of the purchase, the director now owns 26,910 shares in the company, valued at $114,636.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 67,459 shares of company stock valued at $297,135. Corporate insiders own 12.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in STIM. Morgan Stanley grew its stake in shares of Neuronetics by 5,765.4% during the 2nd quarter. Morgan Stanley now owns 110,681 shares of the company’s stock valued at $1,385,000 after purchasing an additional 108,794 shares during the period. Wasatch Advisors Inc. grew its stake in shares of Neuronetics by 21.2% during the 2nd quarter. Wasatch Advisors Inc. now owns 380,398 shares of the company’s stock valued at $4,759,000 after purchasing an additional 66,444 shares during the period. Wells Fargo & Company MN grew its stake in shares of Neuronetics by 19.7% during the 2nd quarter. Wells Fargo & Company MN now owns 393,237 shares of the company’s stock valued at $4,920,000 after purchasing an additional 64,648 shares during the period. Vanguard Group Inc. grew its stake in shares of Neuronetics by 13.9% during the 2nd quarter. Vanguard Group Inc. now owns 489,410 shares of the company’s stock valued at $6,123,000 after purchasing an additional 59,853 shares during the period. Finally, Novo Holdings A S grew its stake in shares of Neuronetics by 11.0% during the 2nd quarter. Novo Holdings A S now owns 582,798 shares of the company’s stock valued at $7,291,000 after purchasing an additional 57,798 shares during the period. Institutional investors and hedge funds own 80.75% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Further Reading: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.